8 Aug 2025 • Comorbid rheumatoid arthritis (RA) doubles the mortality risk in bronchiectasis patients (HR 2.09), with seropositive RA showing an even higher risk (HR 2.34) over a 5.8-year follow-up.

Seronegative RA had a 1.29-fold increase. Use of disease-modifying anti-rheumatic drugs further elevated mortality, highlighting the impact of systemic inflammation.

These findings underscore the urgent need for vigilant management of RA in bronchiectasis patients to potentially mitigate excess mortality.

Source: Sage Journals | Read Full Story